Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival
Objective. To define survival patterns of women with ovarian carcinosarcoma based on patient, tumor, and treatment characteristics. Methods/Materials. A single-institution, retrospective analysis of women diagnosed with ovarian carcinosarcoma from February 1993 to May 2009 was performed. Survival wa...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Obstetrics and Gynecology International |
| Online Access: | http://dx.doi.org/10.1155/2013/490508 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850165819746549760 |
|---|---|
| author | Amelia M. Jernigan Amanda Nickles Fader Benjamin Nutter Peter Rose Jill H. Tseng Pedro F. Escobar |
| author_facet | Amelia M. Jernigan Amanda Nickles Fader Benjamin Nutter Peter Rose Jill H. Tseng Pedro F. Escobar |
| author_sort | Amelia M. Jernigan |
| collection | DOAJ |
| description | Objective. To define survival patterns of women with ovarian carcinosarcoma based on patient, tumor, and treatment characteristics. Methods/Materials. A single-institution, retrospective analysis of women diagnosed with ovarian carcinosarcoma from February 1993 to May 2009 was performed. Survival was analyzed with Cox proportional hazards ratios and Kaplan Meier tests. Results. Forty-seven cases of primary ovarian carcinosarcoma were identified. Age conveyed an HR 3.28 (95% CI 1.51–7.11, P=0.003) for death. Compared to Stages I-II, Stage III carried an HR for death of 4.75 (95% CI 1.16–19.4, P=0.03) and Stage IV disease an HR of 9.13 (95% CI 1.76–47.45, P=0.009). Compared to those with microscopic residual, women with >1 cm diameter of residual disease after primary cytoreductive surgery had an HR for death of 4.71 (95% CI 1.84–12.09, P=0.001). At analysis, 59.1% of those who received platinum-based chemotherapy were alive, compared to 23.1% of those who received nonplatinum-based chemotherapy (P=0.08). Conclusions. Age, stage, and cytoreduction to no gross residual disease are associated with improved survival in women with ovarian carcinosarcoma. Complete surgical cytoreduction should be the goal of surgical management when possible, but the ideal adjuvant treatment regimen remains unclear. |
| format | Article |
| id | doaj-art-e1a181fccff046cb9dd349cd5df0eca7 |
| institution | OA Journals |
| issn | 1687-9589 1687-9597 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Obstetrics and Gynecology International |
| spelling | doaj-art-e1a181fccff046cb9dd349cd5df0eca72025-08-20T02:21:38ZengWileyObstetrics and Gynecology International1687-95891687-95972013-01-01201310.1155/2013/490508490508Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on SurvivalAmelia M. Jernigan0Amanda Nickles Fader1Benjamin Nutter2Peter Rose3Jill H. Tseng4Pedro F. Escobar5Johns Hopkins Hospital, 1800 Orleans Street, Baltimore, MD 21287, USAJohns Hopkins Hospital, 1800 Orleans Street, Baltimore, MD 21287, USACleveland Clinic, 9500 Euclid Avenue, Desk A-81, Cleveland, OH 44195, USACleveland Clinic, 9500 Euclid Avenue, Desk A-81, Cleveland, OH 44195, USAJohns Hopkins Hospital, 1800 Orleans Street, Baltimore, MD 21287, USACleveland Clinic, 9500 Euclid Avenue, Desk A-81, Cleveland, OH 44195, USAObjective. To define survival patterns of women with ovarian carcinosarcoma based on patient, tumor, and treatment characteristics. Methods/Materials. A single-institution, retrospective analysis of women diagnosed with ovarian carcinosarcoma from February 1993 to May 2009 was performed. Survival was analyzed with Cox proportional hazards ratios and Kaplan Meier tests. Results. Forty-seven cases of primary ovarian carcinosarcoma were identified. Age conveyed an HR 3.28 (95% CI 1.51–7.11, P=0.003) for death. Compared to Stages I-II, Stage III carried an HR for death of 4.75 (95% CI 1.16–19.4, P=0.03) and Stage IV disease an HR of 9.13 (95% CI 1.76–47.45, P=0.009). Compared to those with microscopic residual, women with >1 cm diameter of residual disease after primary cytoreductive surgery had an HR for death of 4.71 (95% CI 1.84–12.09, P=0.001). At analysis, 59.1% of those who received platinum-based chemotherapy were alive, compared to 23.1% of those who received nonplatinum-based chemotherapy (P=0.08). Conclusions. Age, stage, and cytoreduction to no gross residual disease are associated with improved survival in women with ovarian carcinosarcoma. Complete surgical cytoreduction should be the goal of surgical management when possible, but the ideal adjuvant treatment regimen remains unclear.http://dx.doi.org/10.1155/2013/490508 |
| spellingShingle | Amelia M. Jernigan Amanda Nickles Fader Benjamin Nutter Peter Rose Jill H. Tseng Pedro F. Escobar Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival Obstetrics and Gynecology International |
| title | Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival |
| title_full | Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival |
| title_fullStr | Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival |
| title_full_unstemmed | Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival |
| title_short | Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival |
| title_sort | ovarian carcinosarcoma effects of cytoreductive status and platinum based chemotherapy on survival |
| url | http://dx.doi.org/10.1155/2013/490508 |
| work_keys_str_mv | AT ameliamjernigan ovariancarcinosarcomaeffectsofcytoreductivestatusandplatinumbasedchemotherapyonsurvival AT amandanicklesfader ovariancarcinosarcomaeffectsofcytoreductivestatusandplatinumbasedchemotherapyonsurvival AT benjaminnutter ovariancarcinosarcomaeffectsofcytoreductivestatusandplatinumbasedchemotherapyonsurvival AT peterrose ovariancarcinosarcomaeffectsofcytoreductivestatusandplatinumbasedchemotherapyonsurvival AT jillhtseng ovariancarcinosarcomaeffectsofcytoreductivestatusandplatinumbasedchemotherapyonsurvival AT pedrofescobar ovariancarcinosarcomaeffectsofcytoreductivestatusandplatinumbasedchemotherapyonsurvival |